» Articles » PMID: 20955707

Bone Disease in Patients with Primary Sclerosing Cholangitis

Overview
Specialty Gastroenterology
Date 2010 Oct 20
PMID 20955707
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Osteopenic bone disease occurs frequently among patients with chronic liver disease but has not been well studied in those with primary sclerosing cholangitis (PSC). We investigated the prevalence, rate of progression, and independent predictors of bone disease in a large number of patients with all stages of PSC.

Methods: Bone mineral density of the lumbar spine, hip, and total body was measured yearly for 10 years in 237 patients with PSC.

Results: Osteoporosis (T-score less than -2.5) was found in 15% of patients and occurred 23.8-fold (95% confidence interval [CI], 4.6-122.8) more frequently in those with PSC than expected from a matched population. By multivariate analysis, age 54 years or older (odds ratio [OR], 7.8; 95% CI, 3.3-18.3), body mass index ≤ 24 kg/m(2) (OR, 4.9; 95% CI, 1.9-12.6), and inflammatory bowel disease for ≥ 19 years (OR, 3.6; 95% CI, 1.5-8.4) correlated with the presence of osteoporosis. Osteoporosis was present in 75% of patients with all 3 risk factors but in only 3.1% of those without all of them. Patients with PSC lost 1% of bone mass per year; this rate of bone loss was significantly associated with duration of inflammatory bowel disease.

Conclusions: Osteoporosis occurs frequently among patients with PSC. Old age, low body mass index, and long duration of inflammatory bowel disease can be used to identify patients with PSC who might derive the most benefit from measurements of bone density and treatments for bone diseases.

Citing Articles

Management of primary sclerosing cholangitis: Current state-of-the-art.

Cancado G, Hirschfield G Hepatol Commun. 2025; 8(12).

PMID: 39774274 PMC: 11567710. DOI: 10.1097/HC9.0000000000000590.


Establishment of a human 3D in vitro liver-bone model as a potential system for drug toxicity screening.

Chen G, Xin Y, Hammour M, Braun B, Ehnert S, Springer F Arch Toxicol. 2024; 99(1):333-356.

PMID: 39503877 PMC: 11742461. DOI: 10.1007/s00204-024-03899-9.


Emerging role of liver-bone axis in osteoporosis.

Gao H, Peng X, Li N, Gou L, Xu T, Wang Y J Orthop Translat. 2024; 48:217-231.

PMID: 39290849 PMC: 11407911. DOI: 10.1016/j.jot.2024.07.008.


Genetic evidence of the causal relationship between chronic liver diseases and musculoskeletal disorders.

Lu Z, Li X, Qi Y, Li B, Chen L J Transl Med. 2024; 22(1):138.

PMID: 38321551 PMC: 10845502. DOI: 10.1186/s12967-024-04941-1.


Caring for the Bone Health Among Liver Transplant Recipients.

Kumar S, Cherian K, Paul T, Goel A J Clin Exp Hepatol. 2023; 13(6):1130-1139.

PMID: 37975037 PMC: 10643275. DOI: 10.1016/j.jceh.2023.05.003.


References
1.
. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

2.
Menon K, Angulo P, Boe G, Lindor K . Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterol. 2003; 98(4):889-92. DOI: 10.1111/j.1572-0241.2003.07341.x. View

3.
Bernstein C, Seeger L, Sayre J, Anton P, Artinian L, Shanahan F . Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995; 10(2):250-6. DOI: 10.1002/jbmr.5650100211. View

4.
Ducy P, Amling M, Takeda S, Priemel M, Schilling A, Beil F . Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000; 100(2):197-207. DOI: 10.1016/s0092-8674(00)81558-5. View

5.
Levy C, Harnois D, Angulo P, Jorgensen R, Lindor K . Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 2005; 25(1):117-21. DOI: 10.1111/j.1478-3231.2005.01026.x. View